Educational dose math only — not medical advice, not a product recommendation, and not a pass/fail on whether a supplement will work for you.
0 100% 150%+

—

Enter label dose

Trial reference

From your label

Per-day total — not per serving unless you take one serving

Enter your label dose — the gauge updates instantly.

Placebo-controlled, 45 women on SSRIs or SNRIs randomised. Remission favoured maca but stayed low in absolute terms — 9.5% vs 4.8% by ASEX and 30% vs 20% by MGH-SFQ — and the benefit clustered in postmenopausal women. Women only; there is no male equivalent of this trial.

Educational only — not medical advice. Disclaimer.

Want the outcome before the arithmetic? The reason check opens any registry entry on this page with its trial result first, then compares your daily intake with the studied amount.

NIH DSLD market slice

Median0.3 g
Products1,239
Below94%

Bulk CSV dump 16 January 2026 · label entries through 2025. Disclosed amounts only — proprietary blends without gram weights excluded.

Trial floors

Primary

Antidepressant-induced sexual dysfunction, women · 3 g over 12 weeks (limited evidence · how we grade this) · Benefit shown — Placebo-controlled, 45 women on SSRIs or SNRIs randomised. Remission favoured maca but stayed low in absolute terms — 9.5% vs 4.8% by ASEX and 30% vs 20% by MGH-SFQ — and the benefit clustered in postmenopausal women. Women only; there is no male equivalent of this trial.

Other floors

  • Dose-finding pilot, 1.5 g arm failed · 1.5–3 g (limited evidence · how we grade this) · Primary endpoint missed — Head-to-head 1.5 g/day vs 3.0 g/day in 20 remitted depressed outpatients, 17 of them women. Only the 3.0 g arm improved significantly on ASEX and MGH-SFQ; 1.5 g/day did not separate. Ten completers. This is the entry's evidence that the lower dose is below the floor, not above it.

  • Men with mild ED, subjective wellbeing · 2.4 g over 12 weeks (limited evidence · how we grade this) · Secondary outcomes only — The only randomised maca trial in men, and it was mild general ED rather than antidepressant-induced. Both arms improved; maca improved more, but IIEF-5 gained only 1.6 points vs 0.5 on placebo — far below the roughly 4-point threshold for a change men notice. The paper frames its own outcome as subjective wellbeing.

Label reading notes

  • Report outcomes by sex, never pooled. The 3 g/day evidence is in women on antidepressants; the men's evidence is a different dose, a different condition, and a subjective endpoint.
  • Trials used gelatinised maca root powder. Extracts, "maca blends" and black/red/yellow varietal claims are not interchangeable at the same gram count.
  • Maca did not change testosterone or oestrogen in healthy men — it is not a hormonal supplement.
  • 3 g/day is a powder-scale dose; capsule products often need six or more servings to reach it.